{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:10:33Z","timestamp":1742962233122,"version":"3.40.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,25]]},"DOI":"10.7759\/cureus.81155","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T13:37:40Z","timestamp":1742909860000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Safety of Dexmedetomidine Dosing Utilizing Adjusted Body Weight in Obese Critically Ill Patients: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Molly E","family":"Robertson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee E","family":"Willett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua  J","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britany N","family":"Sleeckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211021578","article-title":"Evaluation of dexmedetomidine dosing in obese critically ill patients","volume":"36","author":"Atyia SA","year":"2021","unstructured":"Atyia SA, Smetana KS, Tong MC, Thompson MJ, Cape KM, May CC. Evaluation of dexmedetomidine dosing in obese critically ill patients. J Pharm Pract. 2021, 36:67-73. 10.1177\/08971900211021578","journal-title":"J Pharm Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0495.S4-002","article-title":"Understanding the impact of critical illness of drug pharmacokinetics - scientifically robust study design","volume":"37","author":"der Merwe F","year":"2012","unstructured":"der Merwe F, Wallis S, Udy A. Understanding the impact of critical illness of drug pharmacokinetics - scientifically robust study design. J Clin Toxicol. 2012, 37:515-7. 10.4172\/2161-0495.S4-002","journal-title":"J Clin Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1948-2","article-title":"Dexmedetomidine pharmacokinetics in the obese","volume":"71","author":"Cort\u00ednez LI","year":"2015","unstructured":"Cort\u00ednez LI, Anderson BJ, Holford NH, et al.. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015, 71:1501-8. 10.1007\/s00228-015-1948-2","journal-title":"Eur J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03040-z","article-title":"Drug dosing in the critically ill obese patient - a focus on sedation, analgesia, and delirium","volume":"24","author":"Erstad BL","year":"2020","unstructured":"Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient - a focus on sedation, analgesia, and delirium. Crit Care. 2020, 24:315. 10.1186\/s13054-020-03040-z","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0419-5","article-title":"Dexmedetomidine: a review of its use for sedation in the intensive care setting","volume":"75","author":"Keating GM","year":"2015","unstructured":"Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs. 2015, 75:1119-30. 10.1007\/s40265-015-0419-5","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-017-2399-y","article-title":"Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery","volume":"31","author":"Xu B","year":"2017","unstructured":"Xu B, Zhou D, Ren L, Shulman S, Zhang X, Xiong M. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. J Anesth. 2017, 31:813-20. 10.1007\/s00540-017-2399-y","journal-title":"J Anesth"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/OAEM.S17429","article-title":"Sedation with dexmedetomidine in the intensive care setting","volume":"3","author":"Gerlach AT","year":"2011","unstructured":"Gerlach AT, Murphy CV. Sedation with dexmedetomidine in the intensive care setting. Open Access Emerg Med. 2011, 3:77-85. 10.2147\/OAEM.S17429","journal-title":"Open Access Emerg Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221108429","article-title":"Adherence to sedation targets with weight-based propofol and dexmedetomidine in patients with morbid obesity","volume":"57","author":"Hayes E","year":"2023","unstructured":"Hayes E, Esteves A. Adherence to sedation targets with weight-based propofol and dexmedetomidine in patients with morbid obesity. Ann Pharmacother. 2023, 57:232-40. 10.1177\/10600280221108429","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350878-evaluation-of-the-safety-of-dexmedetomidine-dosing-utilizing-adjusted-body-weight-in-obese-critically-ill-patients-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T13:37:42Z","timestamp":1742909862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350878-evaluation-of-the-safety-of-dexmedetomidine-dosing-utilizing-adjusted-body-weight-in-obese-critically-ill-patients-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.81155","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}